# Howden

published a 2026 report on how insurance can support the UK pharmaceutical and life-sciences sector through its current transition, reflecting an active dedicated life-sciences broking practice.


Source: https://en.bioecon.ru/companies/howden/
Updated: 2026-08-18

- Country: United Kingdom

## Verifiable facts

| Fact | Value | Source |
| --- | --- | --- |
| Funding | £4.5 billion equity finance raised by the UK life sciences sector in 2024 (2024-01-01) | https://www.gov.uk/government/publications/life-sciences-competitiveness-indicators-2026/life-sciences-competitiveness-indicators-2026-summary |
| Capacity | 51,800 square metres for advanced therapies manufacturing capacity in 2024 (2024-01-01) | https://www.abpi.org.uk/publications/creating-the-conditions-for-investment-and-growth |
| Headcount | 48,100 people employed in UK pharmaceutical manufacturing in 2022 (2022-01-01) | https://www.gov.uk/government/publications/life-sciences-competitiveness-indicators-2026/life-sciences-competitiveness-indicators-2026-summary |
| Revenue | £24.4 billion market size of the UK pharmaceutical preparations manufacturing industry in 2026 (2026-01-01) | https://img2.ibisworld.com/united-kingdom/industry/pharmaceutical-preparations-manufacturing/1170/ |
| Production site | 26 dedicated UK cell and gene therapy manufacturers in 2023 (2023-01-01) | https://www.icaew.com/library/industry-profiles/pharmaceutical |

Independent sources: abpi.org.uk, gov.uk, icaew.com, img2.ibisworld.com

## Technologies

- [Clinical-trial insurance brokerage](https://en.bioecon.ru/technology/clinical-trial-insurance-brokerage/)